This HTML5 document contains 76 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
schemahttp://schema.org/
rdfshttp://www.w3.org/2000/01/rdf-schema#
skoshttp://www.w3.org/2004/02/skos/core#
phttp://www.wikidata.org/prop/
wikibasehttp://wikiba.se/ontology#
n10http://dx.doi.org/10.1634/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n11http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q37435425
rdf:type
wikibase:Item
schema:description
научни чланак artigo científico scientific article published on 06 April 2009 article científic articolo scientifico vetenskaplig artikel مقالة علمية نشرت في 06 أبريل 2009 bilimsel makale wissenschaftlicher Artikel article scientifique наукова стаття, опублікована у квітні 2009 vědecký článek artículu científicu espublizáu en 2009 vedecký článok wetenschappelijk artikel videnskabelig artikel
p:P577
wds:Q37435425-A51BCE0C-7EAD-41E3-A86D-AD1C0E7350C2
wdt:P577
2009-04-06T00:00:00Z
p:P2093
wds:Q37435425-BCAE3F3F-9D55-4296-8373-3CEFD78BAE4A wds:Q37435425-E17F06CC-E7D1-4F09-945F-E2188A14C33B wds:Q37435425-780251A6-7DC4-47F2-B09D-44A418C4D74F wds:Q37435425-9889C349-4EB7-4AA1-9890-9D794B6B2760 wds:Q37435425-97A0E5FC-408B-4991-97EF-21EE7DE61CD0 wds:Q37435425-1E904A6D-1B4F-45EE-90A0-17A61DC2E2E1 wds:Q37435425-0D1FC0E4-CDD8-4315-A72F-001A2093F600
wdt:P2093
Antonia Del Giudice Ermelinda De Maio Francesco Perrone Maria Carmela Piccirillo Gianfranco De Feo Fabiano Falasconi Jane Bryce
rdfs:label
Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and future directions. Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and future directions. Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and future directions.
skos:prefLabel
Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and future directions. Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and future directions. Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and future directions.
schema:name
Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and future directions. Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and future directions. Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and future directions.
p:P50
wds:Q37435425-13B6DAE4-1E2C-42D1-8A47-1019A072FED5 wds:Q37435425-42A13088-1EA1-4CB1-974F-6B27F6E856FC wds:Q37435425-D5C4885F-75D3-405A-8B48-B42F66FCDD8C
wdt:P50
wd:Q37828902 wd:Q37828910 wd:Q56380768
p:P1476
wds:Q37435425-1B9CCA40-7776-4975-95AB-7C105E0E3054
wdt:P1476
Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and future directions
p:P304
wds:Q37435425-E85908B1-F3B5-4E6F-B37C-5F280072D993
wdt:P304
378-390
p:P31
wds:Q37435425-3758e735-a9ee-4cf5-ab8d-478988c4deae wds:Q37435425-82D1A97A-A51A-4392-8DDF-2EAEDE8F49EF
wdt:P31
wd:Q13442814 wd:Q7318358
p:P921
wds:Q37435425-377182D3-6F25-477E-8D2E-1549FDBB96B4 wds:Q37435425-D9E4D579-84A9-49E2-B098-2E7A29FA9B26
wdt:P921
wd:Q111140 wd:Q7914515
p:P698
wds:Q37435425-EB915E95-31A1-4D3B-BA40-C8CB04905B63
wdtn:P698
n11:19349511
wdt:P698
19349511
p:P1433
wds:Q37435425-21FA1740-5C0C-4A06-BFB9-C686356DA2D2
wdt:P1433
wd:Q2122327
p:P433
wds:Q37435425-02A8CA59-3B03-43E1-B08C-CAD8295B4905
p:P478
wds:Q37435425-78A2FDC1-56DC-453F-BC51-830B38288A03
wdt:P433
4
wdt:P478
14
p:P356
wds:Q37435425-BC543EED-E2A5-4E27-B40D-A035FFCF1646
wdtn:P356
n10:THEONCOLOGIST.2008-0261
wdt:P356
10.1634/THEONCOLOGIST.2008-0261
p:P8608
wds:Q37435425-56D2323E-EBB1-45BE-A191-40BAE0A8AEEE
wdt:P8608
release_bnu3nnj3mfe73pnb7v776npjmu
p:P5875
wds:Q37435425-2A333137-B774-448B-BC7B-40FCB4E1C627
wdt:P5875
24260559